Biomarkers and Targeted Therapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%–3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554/ |